Blog
RSS FeedPosted by Michael Wonder on 09 Jan 2020
Alignment of terminology
9 January 2020 - CADTH is aligning the terminology in the single drug review processes as follows: ...
Posted by Michael Wonder on 09 Jan 2020
New CADTH process for cell and gene therapies
9 January 2020 - CADTH has undertaken an internal review of our processes for drugs and devices, and established a revised ...
Posted by Michael Wonder on 01 Dec 2019
The ‘Top 10’ challenges for health technology assessment: INAHTA viewpoint
28 November 2019 - The International Network of Agencies for Health Technology Assessment (INAHTA) spans the globe as a network of ...
Posted by Michael Wonder on 28 Nov 2019
Takhzyro (lanadelumab injection) receives positive recommendation from CADTH's Canadian Drug Expert Committee for the routine prevention of hereditary angioedema attacks
22 November 2019 - The positive recommendation is supported by the recently released findings of the Phase 3 Help Study™ Open-Label ...
Posted by Michael Wonder on 23 Nov 2019
Santen receives CADTH Canadian Drug Expert Committee reimbursement recommendation for Verkazia (cyclosporin 0.1%) eye drops
22 November 2019 - Santen Canada announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee ...
Posted by Michael Wonder on 22 Nov 2019
Revised process for cell and gene therapies
21 November 2019 - CADTH has undertaken an internal review and established a novel process for the review of cell and ...
Posted by Michael Wonder on 18 Nov 2019
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada
15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...
Posted by Michael Wonder on 03 Oct 2019
Dr. Brian O’Rourke to retire as CADTH’s President and CEO
3 October 2019 - Dr. Brian O’Rourke has announced his intention to retire from CADTH, effective 31 March 2020. ...
Posted by Michael Wonder on 18 Sep 2019
Health technology agency insights: informing modification of a qualitative benefit risk framework for health technology reassessment of prescription medications
16 September 2019 - This study's intent was to determine if a qualitative benefit risk framework could be used or modified ...
Posted by Michael Wonder on 22 Aug 2019
Updated procedure and submission guidelines for the CADTH Common Drug Review
22 August 2019 - The Procedure and Submission Guidelines for the CADTH Common Drug Review has been updated with the ...
Posted by Michael Wonder on 01 Aug 2019
Proposal to enhance the transparency of CADTH’s review reports and recommendations
31 July 2019 - CADTH is committed to increasing the transparency of its health technology assessment processes. ...
Posted by Michael Wonder on 30 May 2019
Use of real world data sources for Canadian drug pricing and reimbursement decisions: stakeholder views and lessons for other countries
29 May 2019 - Canada has a long history of the use of clinical evidence to support health care decision making. ...
Posted by Michael Wonder on 23 May 2019
Biosimilars no longer reviewed through the CADTH CDR and pCODR processes
23 May 2019 - When CADTH launched a new, streamlined biosimilar review process in February 2018, we committed to evaluating ...
Posted by Michael Wonder on 23 Apr 2019
Additional embargo period following revised CDEC recommendations
17 April 2019 - Effective immediately, CADTH has revised its procedures for the CADTH Common Drug Review to permit an ...
Posted by Michael Wonder on 25 Mar 2019
One Canadian payer's experience with biosimilars
25 March 2019 - Much of the discussion about biosimilar uptake revolves around challenges in the United States, but other ...